BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/2/2024 8:41:38 AM | Browse: 174 | Download: 846
 |
Received |
|
2024-03-14 01:37 |
|
Peer-Review Started |
|
2024-03-14 01:37 |
|
First Decision by Editorial Office Director |
|
2024-05-24 06:32 |
|
Return for Revision |
|
2024-05-24 06:32 |
|
Revised |
|
2024-05-28 14:44 |
|
Publication Fee Transferred |
|
2024-06-15 06:57 |
|
Second Decision by Editor |
|
2024-06-13 02:45 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-13 09:15 |
|
Articles in Press |
|
2024-06-13 09:15 |
|
Edit the Manuscript by Language Editor |
|
2024-06-20 19:40 |
|
Typeset the Manuscript |
|
2024-06-28 08:13 |
|
Publish the Manuscript Online |
|
2024-07-02 08:41 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kyeong-Hoon Park, Jeong-Ju Yoo, Sang Gyune Kim and Young Seok Kim |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Soonchunhyang University Research Fund |
20240007 |
|
| Corresponding Author |
Jeong-Ju Yoo, MD, PhD, Associate Professor, Department of Gastroenterology and Hepatology, Soonchunhyang University School of Medicine, 170 Jomaruro Wonmigu, Bucheonsi Gyeonggido, Bucheon 14584, South Korea. puby17@naver.com |
| Key Words |
Adverse events; Atezolizumab; Bevacizumab; Complication; Hemorrhage; Bleeding; Hepatocellular carcinoma; Case report |
| Core Tip |
Our study delves into the emerging therapy of atezolizumab/bevacizumab for unresectable hepatocellular carcinoma (HCC), contrasting its efficacy with traditional treatments like sorafenib. We highlight the real-world challenges of bleeding complications, particularly intratumoral bleeding, associated with bevacizumab. Presenting a rare case, we emphasize the need for proactive measures, such as baseline examinations, to mitigate bleeding risks before initiating atezolizumab/bevacizumab. Our findings underscore the critical importance of vigilant monitoring and prompt intervention to address potentially fatal complications during atezolizumab/bevacizumab therapy, contributing to the evolving understanding of HCC treatment strategies. |
| Publish Date |
2024-07-02 08:41 |
| Citation |
Park KH, Yoo JJ, Kim SG, Kim YS. Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report. World J Clin Cases 2024; 12(22): 5177-5183 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i22/5177.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i22.5177 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
